KYTHERA Biopharmaceuticals, Inc. (KYTHERA) announced that it has initiated a firstinhuman, proofofconcept study evaluating the safety, tolerability, persistence and histological effects of ATX104, a lightactivated facial contouring agent.

“We are very excited to move ATX104 into the clinic,” said Patricia Walker, MD, PhD, KYTHERAs Chief Medical Officer. “In preclinical testing, KYTHERAs proprietary photofiller demonstrated improved persistence, maintenance of shape and contourability a combination of features not available in current dermal fillers. We see this as a nextgeneration filler platform that has the promise of dramatically expanding the landscape of possible aesthetic treatments.”

“The initiation of this ATX104 trial marks an important milestone for KYTHERA. ATX104 represents our third clinical stage product and the first based on our own Research programs,” said Keith Leonard, President and CEO of KYTHERA. “With the data from this initial proofofconcept trial, we intend to evaluate worldwide partnership options for ATX104.”

About ATX104

ATX104 is a lightactivated facial contouring agent, based on a proprietary technology codeveloped by KYTHERA and Johns Hopkins University. ATX104 is designed to be injected, shaped and polymerized transdermally via an external light source. Transdermal photopolymerization enables an alteration of ATX104 mechanical properties in situ. In preclinical models, ATX104 photochemistry, when combined with all tested commercially available fillers, dramatically improved the persistence and ability to maintain a contoured shape as compared with the filler alone.

Source